Treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections by high penetration prodrugs
AssigneeTechfields Inc.
InventorsChongxi YU, Lina XU
Life of this patent
Estimating the term…
Abstract
High penetration prodrugs (HPPs), pharmaceutical compositions and methods thereof, for treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections are disclosed. The HPPs are capable of penetrating one or more biological barriers to reach areas that their corresponding parent drugs may not be able to reach with sufficient quantities. While the HPPs can be administered to a subject through various administration routes, e.g., local delivery or systemic administration, transdermal or topical administration of them provides various additional advantages over use of the parent drugs.
Claims20
A method of treating a sign, symptom, and/or complication of a viral, bacterial, protozoal, and/or fungal infection, or a related condition thereof in a subject, comprising administering a high penetration prodrug (HPP) of Structure L-1:
- or a stereoisomer or pharmaceutically acceptable salt thereof to the subject, wherein:
- F, as a functional unit, is a molecular moiety of an active pharmaceutical ingredient selected from 5-lipoxygenase-activating protein (FLAP) inhibitors, 5-lipoxygenase inhibitors, leukotriene receptor antagonists, and anti-inflammatory agents;
- T, as a transportational unit, is a basic group comprising a protonatable nitrogen;
- L1, L2, and L4 together form a linker such that the compound of Structure L-1 is capable of being hydrolyzed or metabolized under physiological conditions to release the functional unit F to form the active pharmaceutical ingredient, or a biologically active metabolite thereof.
Dependencies are inferred from the claim text.